Therapy and Long-Term Prophylaxis of Vaccinia Virus Respiratory Infections in Mice with an Adenovirus-Vectored Interferon Alpha (mDEF201) by Smee, Donald F. et al.
Therapy and Long-Term Prophylaxis of Vaccinia Virus
Respiratory Infections in Mice with an Adenovirus-
Vectored Interferon Alpha (mDEF201)
Donald F. Smee
1*, Min-Hui Wong
1, Andrew Russell
1, Jane Ennis
2, Jeffrey D. Turner
2
1Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah, United States of America, 2Defyrus, Inc.,
Toronto, Ontario, Canada
Abstract
An adenovirus 5 vector encoding for mouse interferon alpha, subtype 5 (mDEF201) was evaluated for efficacy against lethal
vaccinia virus (WR strain) respiratory infections in mice. mDEF201 was administered as a single intranasal treatment either
prophylactically or therapeutically at doses of 10
6 to 10
8 plaque forming units/mouse. When the prophylactic treatment was
given at 56 days prior to infection, it protected 90% of animals from death (100% protection for treatments given between
1–49 days pre-infection), with minimal weight loss occurring during infection. Surviving animals re-challenged with virus 22
days after the primary infection were protected from death, indicating that mDEF201 did not compromise the immune
response against the initial infection. Post-exposure therapy was given between 6–24 h after vaccinia virus exposure and
protection was afforded by a 10
8 dose of mDEF201 given at 24 h, whereas a 10
7 dose was effective up to 12 h. Comparisons
were made of the ability of mDEF201, given either 28 or 1 day prior to infection, to inhibit tissue virus titers and lung
infection parameters. Lung, liver, and spleen virus titers were inhibited to nearly the same extent by either treatment, as
were lung weights and lung hemorrhage scores (indicators of pneumonitis). Lung virus titers were significantly (.100-fold)
lower than in the placebo group, and the other infection parameters in mDEF201 treated mice were nearly at baseline. In
contrast, viral titers and lung infection parameters were high in the placebo group on day 5 of the infection. These results
demonstrate the long-acting prophylactic and treatment capacity of mDEF201 to combat vaccinia virus infections.
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Introduction
The threat of using orthopoxviruses, variola and monkeypox, as
bioterror weapons has led to increases in vaccination particularly
in military personnel as well as the investigation of countermea-
sures (antiviral treatments) for such infections [1]. A number of
compounds have been identified that exhibit direct antiviral
activity against these and related poxviruses in animal models
[2,3]. From these investigations, three compounds stand out as
being clinical candidates, cidofovir [4], CMX001 (an orally active
prodrug of cidofovir) [5], and ST-246 [6]. Cidofovir, CMX-001,
and ST-246 have all been used in emergency settings to treat
vaccination complications [7,8].
Immune system stimulation via exogenous recombinant inter-
feron (rIFN) is effective for treating vaccinia virus respiratory
infections in mice [9]. Single daily doses of rIFNa or rIFNc
rescued mice from lethality when administered 1–2 days after virus
challenge and reduced lung virus titers. Both vaccinia keratitis and
vaccinia-induced skin lesions were treated with rIFN (topically and
injected respectively) in monkey models with success [10,11].
Vaccinia and other poxviruses have evolved comprehensive
mechanisms to antagonize the interferon system [12], that include
blocking IFN gene induction, disrupting extracellular and
intracellular signaling and slowing IFN induced gene (PKR and
2959 OAS) activation. Treatment with exogenous rIFN only
compensates for host IFN gene suppression and swamping the IFN
binding protein so it must begin early after infection before the
virus suppresses activation of the antiviral state. Interferon has
a short half-life of three hours [13], which requires frequent
treatment with large bolus doses resulting in commensurate
adverse effects often leading to patient-initiated cessation of
treatment [14,15]. Pegylated rIFN has improved the in vivo
half-life to allow for weekly injections, but results in a reduced
activity of the protein and an increased cost.
A needle-free, single dose drug capable of achieving steady-state
method of delivering interferon would maximize the therapeutic
benefits of IFN, while minimizing the bolus-induced toxicity. To
this end, a replication-deficient adenovirus 5 (Ad5) vector
containing the human consensus interferon alpha gene, referred
to as DEF201, has been developed. Intranasal administration of
DEF201 allows for the Ad5 vector to infect respiratory cells and
drives constitutive expression of the IFN transgene and secretion of
fully glycosylated IFN. Ad5-vectored mouse interferon (mDEF201)
resulted in sustained IFN levels [16], that completely protected
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26330mice from a lethal Western equine encephalitis virus infection
when given intramuscularly at 10
7 plaque forming units (PFU)/
mouse up to 7 days prior to virus challenge [16]. Against
Venezuelan equine encephalitis virus infection, mDEF201
prevented death when administered intramuscularly at 10
7
PFU/mouse 24 h prior to infection but not when given 6 h
after infection [17]. Intranasally-administered mDEF201 was
also used to treat mice infected intranasally with SARS virus
(resulting in a lethal respiratory infection) [18]. It was 100%
protective when administered prophylactically at 10
6 PFU/
mouse up to 14 days pre-virus exposure, with similar protection
afforded by a 10
8 dose administered therapeutically at 12 h after
infection [18].
Adenoviral vectored human consensus IFN (DEF201), was
recently used intranasally to treat hamsters infected intraperito-
neally with yellow fever virus (resulting in a lethal hepatic
infection) [19]. Protection from death was observed for single
administrations of DEF201 at 10
7.5 PFU/animal given 7 days
before to 2 days after virus challenge, which demonstrated both
prophylaxis and therapy in this model. DEF201 treatment reduced
yellow fever virus titers in liver and spleen, and resulted in
decreases in serum alanine transaminase levels.
Herein, mDEF201 was evaluated for prophylaxis and therapy of
vaccinia virus (WR strain) respiratory infections in mice. In this
model the virus infection spreads systemically to include other
tissues besides the lungs, particularly the liver and spleen [20].
Increases in lung weight and lung hemorrhage (indicative of
pneumonitis) are hallmarks of vaccinia infection, as is severe body
weight loss. The results show that a single intranasal dose of
mDEF201 produced a remarkably prolonged 8-week prophylactic
effect, and was also active therapeutically.
Materials and Methods
Ethics statement
The experiments were conducted in accordance with Protocol
552 approved by the Institutional Animal Care and Use
Committee of Utah State University. The work was done in the
AAALAC-accredited Laboratory Animal Research Center of
Utah State University in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals
(Revision; 2010).
Animals
Female BALB/c mice (Charles River Labs, Wilmington, MA)
weighing approximately 13–15 g at the time of first treatment
were used. After a 48-hour quarantine period the animals were
randomly assigned to cages. All work with these animals was
performed in the Biosafety Level 2 area of the AAALAC-
accredited Laboratory Animal Research Center at Utah State
University.
Test materials
The adenovirus vectored mouse interferon alpha, subtype 5
construct mDEF201 was prepared at the Robert Fitzhenry Vector
Laboratory (McMaster University, Hamilton, Canada). The
methods of preparation have been described previously [16].
Briefly, the mouse interferon alpha gene (subtype 5) was cloned
into a replication deficient Ad-5 vector (deletions of E1 and E3
gene deletions), amplified in 293 cells and purified by cesium
chloride gradient centrifugation. Stock solutions of mDEF201
were stored at 280uC and were thawed on ice and diluted in
saline to the appropriate dose immediately prior to a single
administration. Gilead Sciences (Foster City, CA) provided the
positive control compound cidofovir.
Virus
Vaccinia virus (WR strain) was purchased from the American
Type Culture Collection (ATCC, Manassas, VA). The virus was
propagated in African green monkey kidney (MA-104) cells (from
MA Bioproducts, Walkersville, MD) for use in these studies.
Experimental design for animal studies
Mice were anesthetized with ketamine/xylazine (50/5 mg/kg) by
intraperitoneal (i.p.) injection for intranasal treatments and intrana-
sal infection. The animals were initially infected intranasally with
approximately 1–2610
5 PFU of vaccinia virus in a 50-mlv o l u m e .
mDEF201 was administered intranasally (50-ml) either prior to or
after vaccinia virus exposure, according to the experimental
Table 1. Effects of treatment with mDEF201 and cidofovir on survival of mice from a vaccinia virus (WR strain) respiratory
infection.
Lung Infection Parameters (Day 5)
Compound (dose)
a
Treatment Start
TIme
b
Survivors/
Total MDD
c ± SD
Hemorrhage
Score Weight (mg)
Virus Titer (Log10
PFU/g)
mDEF201 (10
7) 224 h 10/10*** - 0.060.0** 128613** 5.860.6**
mDEF201 (10
6) 224 h 10/10*** - 0.060.0** 130612** 6.661.0**
mDEF201 (10
5) 224 h 9/10*** 13.0 0.160.2** 188619* 7.860.1**
Cidofovir (100) +24 h 10/10*** - 0.060.0** 146611** 7.160.2**
Ad-5 empty vector (10
7) 224 h 0/10 6.860.6 1.060.5 260658 8.760.1
Placebo 224 h 0/20 7.161.0 1.860.3 310666 8.760.1
amDEF201 and empty vector are PFU/mouse doses, whereas the dose of cidofovir is mg/kg/day. mDEF201, the Ad-5 empty vector, and the placebo groups were given
single intranasal treatments. Cidofovir was administered by intraperitoneal route once a day for two days. For consistency with the other groups, the cidofovir group
also received saline intranasally at 224 h.
bRelative to intranasal virus exposure (1610
5 PFU).
cMean day of death of animals that died on or before day 21 of the infection.
*P,0.05.
**P,0.01.
***P,0.001, compared to placebo.
doi:10.1371/journal.pone.0026330.t001
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maintain consistency since intranasal treatment alters the environ-
ment for infection, all mice were given intranasal saline when the
mDEF201 treatments were given 1 day before or after virus
infection, or else additional placebo groups were used to accommo-
date delivery of intranasal liquid. All animals were weighed every
other day. In some instances a normal control group (untreated,
uninfected) of 10 mice was maintained throughout the study.
For certain studies, the normal control group was infected with
virus at the end of the initial 21-day antiviral study to serve as
naı ¨ve, infected controls for the re-infection. Treated mice surviving
the primary infection were re-infected on day 22 with approxi-
mately 5610
5 PFU units of vaccinia virus in a 50-ml volume. This
dose was larger than for the primary infection to account for the
increased age of the mice, and older mice are less susceptible to
vaccinia infection. The age-matched normal control (naı ¨ve)
animals were infected for the first time with the same virus
challenge. Survival and body weights in these groups were
determined over a 21-day period.
Separate animals were maintained for determination of tissue
virus titers, lung hemorrhage scores, and lung weights. Groups of 5
infected mice per day were sacrificed for removal of tissues. Lungs
were given a hemorrhage score (color change from pink to plum
which occurs regionally in the lung rather than gradually over the
entire lung) ranging from 0 to 4 (entire lung affected). Lungs,
spleens, livers, and snouts were weighed prior to homogenization
which releases infectious virus for titration. Homogenization of soft
tissues was done in 1 ml of cell culture medium using a stomacher.
Snouts were ground in 1 ml of medium using sterilized mortars and
pestles. Samples were serially diluted in 10-fold increments and
plaque titrated in 12-well microplates of Vero cells. Plaques were
stained at three days with 0.2% crystal violet in 10% buffered
formalin, then the plaques were counted with the aid of a light box.
Plaque numbers were converted to PFU per gram of infected tissue.
Statistical analysis
Initially, survivor numbers were compared by multiple group chi
square analysis. When statistical significance was found, survivor
numbers were evaluated using the two-tailed Fisher exact test.
Differences in the mean day of death, tissue virus titers, lung
weights, and lung hemorrhage scores were statistically analyzed
using the two-tailed Mann-Whitney U-test. Analyses were per-
formed using the InStatH computer software program (GraphPad
Software, San Diego, CA), comparing treated and placebo groups.
Results
Short-term mDEF201 prophylaxis is completely
protective against lethal challenge
The short-term prophylactic activity of mDEF201 administered
at various intranasal doses one day prior to virus challenge is
presented in Table 1. mDEF201 was uniformly, 90–100%
protective from a lethal vaccinia challenge at doses of 10
5 to 10
7
PFU/animal. This protective effect can be attributed to the mIFN
transgene because the empty adenovirus vector was not protective
and produced similar complete mortality as the placebo control.
Cidofovir (positive control compound) was also 100% protective at
100 mg/kg/day when administered by intraperitoneal route
starting 1 day post-infection. Table 1 also shows the effects of
treatment with mDEF201 and cidofovir on lung infection
parameters. A dose-responsive effect on lung virus titer was seen
with mDEF201 treatments, with the highest dose causing nearly
an 800-fold reduction in lung virus titer. mDEF201 doses of 10
5
and 10
6 PFU/mouse reduced virus titers 8- and 125-fold,
respectively. All three mDEF201 treatments significantly reduced
lung weights and lung hemorrhage scores. In contrast, cidofovir
treatment caused a only a 40-fold reduction in virus titer, and
protected lungs from virus-induced pathology. Lung virus titers
and lung weights were also intermediate between the 10
5 and 10
6
mDEF201 dosage groups. Neither the control, nor adenovirus
empty vector inhibited lung infection parameters.
Extended prophylaxis of vaccinia infection with a single
mDEF201 administration
To measure the window of prophylactic activity, 10
7 PFU/mouse
of mDEF201 was administered at various times prior to virus
infection (Table 2). In the first experiment a single dose of mDEF201
was 100% protective when administered between 28 days and 1 day
pre-virus exposure. Mean body weights during the course of the
primary infection are presented in Figure 1A. All of the treatments
with mDEF201 largely protected the animals against weight loss. A
slightdropinweightoccurredonday1followingintranasalexposure
tovirus,butthemicewerebacktotheinitialstartingweightbyday3.
Seven placebo-treated animals survived the infection, differing from
that of Table 1 where no animals survived. This likely occurred
because the mice at the time of infection were 28 days older, and
Table 2. Effects of extended prophylaxis with mDEF201 on
survival of mice from primary respiratory infection and
reinfection with vaccinia virus (WR strain).
Compound
a
Treatment
Start Time
b
Primary Infection
Survivors/Total
Reinfection
Survivors/Total
Experiment 1:
mDEF201 228 days 10/10** 10/10***
mDEF201 221 days 10/10** 10/10***
mDEF201 214 days 10/10** 10/10***
mDEF201 27 days 10/10** 10/10***
mDEF201 23 days 10/10** 10/10***
mDEF201 21 day 10/10** 10/10***
Placebo 21 day 7/20 7/7***
Naı ¨ve Control
c - 10/10 0/10
Experiment 2:
mDEF201 256 days 9/10*** 9/9***
mDEF201 249 days 10/10*** 10/10***
mDEF201 242 days 10/10*** 10/10***
mDEF201 235 days 10/10*** 10/10***
mDEF201 228 days 10/10*** 10/10***
mDEF201 21 day 10/10*** 10/10***
Placebo 21 day 0/20 -
Naı ¨ve Control
c - 10/10 0/10
aThe mDEF201 intranasal dose of 10
7 PFU/mouse was given only once. All
animals not receiving mDEF201 on day -1 were treated intranasally with saline
on that day.
bRelative to the primary infection. In Experiment 1 the primary intranasal
challenge was 1610
5 PFU of virus. Since this challenge dose failed to cause
100% mortality (as mice age their susceptibility to infection wanes), the
primary virus challenge dose for Experiment 2 was increased to 2.5610
5 PFU.
Reinfection of both sets of mice was performed intranasally with 5610
5 PFU of
virus.
cUninfected, untreated for the primary infection, but infected at 22 days.
**P,0.01.
***P,0.001, compared to placebo (primary infection) or naı ¨ve control
(reinfection).
doi:10.1371/journal.pone.0026330.t002
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weight loss in the placebo group persisted until day 11 of the
infection. After that time, the seven animals that survived the
infection began to recover body weight.
The surviving mice from experiment 1 were re-infected with a
5-fold higher challenge of vaccinia virus than was originally given,
and all of these animals survived the re-challenge (Table 2).
Infection of age-matched naı ¨ve mice resulted in expected 100%
mortality. Weight loss occurred in all mDEF201 treated groups,
but was much less severe than in naı ¨ve, infected mice (Figure 1B).
Rebound from weight loss during the re-infection was fastest in the
placebo group. This group contained the most seriously afflicted
animals during the primary infection, thus would be expected to
have a more robust immune response than treated animals that
did not get as sick.
Based upon the successful extended prophylaxis up to 28 days
pre-infection, a second experiment (Table 2) was initiated using
starting times as early as 56 days before virus challenge. mDEF201
was 90% protective when administered at -56 days, and 100%
protective when given at all shorter time points (,49 days).
Because the virus challenge dose was higher than that given in
Experiment 1 (see footnote ‘‘b’’ in Table 2), the result was that all
placebo-treated animals in Experiment 2 died from the primary
infection. Minimal weight loss occurred in groups treated
prophylactically with mDEF201 (Figure 1C). Decreases in body
weight in mDEF201 groups were primarily seen on days 5–9 of the
infection, with the nadir being day 7.
The surviving mice that were treated with mDEF201 in the
second experiment (Table 2) were re-infected with a 2-fold higher
challenge of vaccinia virus, and all of these animals survived.
Infection of age-matched naı ¨ve mice resulted in 100% mortality.
Weight loss occurred in all mDEF201 treated groups, but was
minimal and occurred on days 3–5 (Figure 1D). This is in contrast
to the rapid weight decline in naı ¨ve, infected mice. Body weights
during the re-infection were similar for most mDEF201 groups.
Slightly less rapid recovery in body weight over 21 days was seen
in the mDEF201 group treated prophylactically at -56 days
compared to the other treated groups.
Viral titers in various tissues were determined from mice treated
with mDEF201 either at 28 days or 1 day prior to infection. Lung
virus titers in mDEF201 treated groups were at least 100-fold less
thaninplacebotreated mice(Figure2A).Liverand spleen virustiters
were below or near the level of detection in animals treated with
mDEF201, but increased over time in placebos (Figures 2B and 2D).
Snout virus titers in mDEF201 treated groups were significantly less
than placebos on day 3 but not on day 5 (Figure 2F). In comparing
virus titers in the -28 day mDEF201 group to that of the -1 day
mDEF201 group, the amounts of detectable virus were nearly
equivalent in lung, liver and spleen. Differences were observed in
snout virus titers between these two groups, but due to variability the
differences were not statistically significant.
Lung weights and lung hemorrhage scores were determined in
infected mice in parallel with the determination of viral titers.
Lung weights in mDEF201 treated animals were near normal,
whereas on day 5 the placebos exhibited a large increase in lung
weight (Figure 2C). Similarly, lung scores were near normal in the
two groups treated with mDEF201, but were severe on day 5 in
the placebo group (Figure 2E). The extent of inhibition of lung
Figure 1. Effects of prophylaxis with mDEF201 on percent body weights of mice during vaccinia virus (WR strain) respiratory
infections. (A) Experiment 1, primary infection, (B) Experiment 1, reinfection, (C) Experiment 2, primary infection, (D) Experiment 2, reinfection.
Intranasal treatments with mDEF201 (10
7 PFU/mouse) were given one time only on the indicated day prior to virus exposure. In Experiment 1 the
primary intranasal challenge was 1610
5 PFU of virus. Since this challenge dose failed to cause 100% mortality (as mice age their susceptibility to
infection wanes), the primary virus challenge dose was increased to 2.5610
5 PFU of virus for Experiment 2. Reinfection of both sets of mice was
performed intranasally with 5610
5 PFU of virus. The data accompany those of Table 2. Thus, the initial number of mice per group for each figure
corresponds to the total number per group in the table.
doi:10.1371/journal.pone.0026330.g001
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seen in the -1 day mDEF201 group.
The results from these experiments indicate that mDEF201 has
an extremely long-acting prophylactic activity against vaccinia
virus infections in mice. Only in animals treated 56 days prior to
infection was there a hint of waning activity, since one animal died
from the infection in that group.
Therapy of infection with mDEF201
mDEF201 at two different doses was administered after
infection to combat a vaccinia virus infection. Preliminary studies
with low dose mDEF201 (10
5 or 10
6 PFU/mouse), given at 6, 12,
or 24 h after infection provided no protection from the lethal
infection (data not shown). However, higher doses of mDEF201
(10
8 PFU/mouse) were 100% protective when administered either
at 6, 12, or 24 h after infection (Table 3). A 10
7 PFU/mouse dose
was 80–90% protective when given at 6 and 12 hours, but only
30% protective when administered at 24 hours. Survival time in
the lower dosage group receiving treatment at 24 hours was
significantly increased relative to the placebo control. Cidofovir
was 100% protective when administered at 100 mg/kg/day for
two days starting at 24 h.
Body weight changes for treatments with 100% survival during
the course of the infection are shown in Figure 3 (10
8 mDEF201
and cidofovir). Weight loss in mDEF201 treated mice increased
with longer delay to commencement of treatment, with all animals
regaining their pre-challenge weight by day 18 of the experiment.
Given the weight loss in the +24h group, further delays in
treatment would likely result in some mortality. Mice treated daily
with cidofovir starting 24h post-vaccinia challenge lost less weight.
Discussion
In these studies, a single intranasal dose of mDEF201 was found
to exhibit a potent prophylactic activity that endured for at least 56
days. An endpoint in the duration of the protection could not be
projected because treatment at -56 days resulted in only one death
Figure 2. Effects of prophylaxis with mDEF201 given on day -28 or day -1 on infection parameters in mice infected intranasally with
vaccinia virus (WR strain). (A) Lung virus titer, (B) liver virus titer, (C) lung weight, (D) spleen virus titer, (E) lung hemorrhage score, (F) snout virus
titer. Intranasal treatments with mDEF201 (10
7 PFU/mouse) were given one time only on the indicated day prior to intranasal virus exposure (2.5610
5
PFU). There were no survivors in the placebo group on day 7 for data determinations. This experiment was conducted concurrently with the second
experiment in Table 2. Each data point represents the mean for five animals per group.
doi:10.1371/journal.pone.0026330.g002
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weight loss during infection for the -56 day treatment group was
equivalent to the -1 day treatment group. Investigation of other
parameters of infection (tissue virus titers, lung weights, and lung
hemorrhage scores) revealed that the inhibition of these param-
eters with a -28 day mDEF201 treatment was quite comparable to
that of a -1 day treatment. Prophylaxis starting a day before
infection could effectively be achieved with doses of 10
5 through
10
7 PFU/mouse. Extended prophylaxis up to 56 days pre-
infection was only investigated at the 10
7 dose.
Other investigators have shown that DEF201 in both mouse
and human constructs are active prophylactically [16,17,18,19].
Kumaki et al. showed 100% protection against SARS infection in
mice by a 10
6 dose given only at -14 days (other time points were
not assessed) [17]. Thus, it is possible that prophylaxis earlier than
14 days would be protective against SARS infection. Against
yellow fever virus infections in hamsters, DEF201 was effective
when given 7 days prior to infection but not at -21 days [19]. This
breadth of viral efficacy indicates the potential of DEF201 to
function as a truly broad-spectrum antiviral.
Remarkably, mDEF201 was effective in mice against vaccinia
virus infection when given nearly two months prior to virus
exposure. This indicates that Ad5-vectored IFN induced a long-
term antiviral state that was completely protective with a single
dose. This extended prophylaxis appears to exist in the absence of
measurable serum IFN levels, since Wu et al. [15] were only able
to detect interferon alpha protein in mice treated intramuscularly
with mDEF201 at 24 and 48 h, but not at 7 days (times in between
were not investigated).
This study raises a number of important questions relative to the
long acting protective effect of mDEF201 against vaccinia virus
infection in mice. Questions such as how much interferon is
produced, how long is it produced, and what cells are respon-
sible for producing it are being asked and are currently
under investigation. It has already been shown that interferon is
successfully produced by the vector when administered intramus-
cularly to mice and the protein is detectable in the serum [16].
From that work we also know that the levels of interferon rise very
quickly (within 3-5 h), are transiently high, and come down within
several days. We can infer that the interferon protein will be
delivered successfully to the lung and nostrils (and have since
confirmed this in a separate study, unpublished). Given that the
protection lasts longer than the previously measured levels of
interferon protein persist, we assume that the interferon is
activating an immunological cascade that then protects the animal
from infection by inducing an antiviral state. Thorough investi-
gation of induced genes, length of induction, and localization of
induction are planned, but are beyond the scope of this study.
The choice of intranasal route of administration is important, as
this route has been demonstrated to bypass pre-existing immunity
to the adenovirus vector [21]. Intranasal delivery is also less
invasive and easier to administer to large numbers of patients in
the event of a mass infection due to a natural outbreak or
intentional release. Adenovirus was selected to be the vector for
interferon due to its rapid infectivity, breadth of human safety
data, and facility of intranasal administration. mDEF201,
administered by intranasal route, has already been shown to be
effective in the treatment of SARS coronavirus respiratory
infections in mice [18]. This is the first description of adenoviral
vectored interferon alpha being used, by any route, to prevent or
treat vaccinia virus infections.
A limited therapeutic window of time exists for treating vaccinia
virus infections with interferon-based drugs like mDEF201, and to
achieve treatment higher doses of mDEF201 are needed than for
prophylaxis. Indeed, low dose mDEF201 (10
5–10
6 PFU/mouse)
that were effective prophylactically were not effective when
administered even 6 h after infection. Higher doses (10
8 PFU/
mouse) were required for full protection from lethality when given
at +24 h, however considerable body weight loss resulted due to
infection (Figure 3). The single 10
8 dose administered at 24 h was
not as effective as daily doses of 100 mg/kg of cidofovir that acts
directly on vaccinia to inhibit replication. This may be due in part
Table 3. Effects of therapy with mDEF201 and cidofovir on
survival of mice from a vaccinia virus (WR strain) respiratory
infection.
Compound
(Dose)
a
Treatment
Start Time Survivors/Total MDD
b ± SD
mDEF201 (10
8) +6 h 10/10*** -
mDEF201 (10
7) +6 h 9/10*** 8.0
Placebo +6 h 0/10 6.860.6
mDEF201 (10
8) +12 h 10/10*** -
mDEF201 (10
7) +12 h 8/10*** 9.062.8
Placebo +12 h 0/10 7.160.3
mDEF201 (10
8) +24 h 9/9*** -
mDEF201 (10
7) +24 h 3/10 9.662.8**
Cidofovir (100) +24 h 10/10*** -
Placebo +24 h 0/10 7.160.3
aThe doses of mDEF201 are in PFU/mouse units, whereas the dose of cidofovir
is in mg/kg/day units. mDEF201 was given as a single intranasal treatment, as
was the placebo Cidofovir was administered by intraperitoneal route once a
day for two days. For consistency with the other groups, the cidofovir group
also received intranasal saline at 24 h.
bMean day of death for mice that died on or before day 21 of the infection. The
mice were inoculated intranasally with 1610
5 PFU of virus to initiate the
infection.
**P,0.01.
***P,0.001, compared to placebo.
doi:10.1371/journal.pone.0026330.t003
Figure 3. Effects of therapy with mDEF201 and cidofovir on
percent body weights of mice during a vaccinia virus (WR
strain) respiratory infection. Intranasal treatments with mDEF201
(10
8 PFU/mouse) were given one time. Cidofovir (100 mg/kg/day) was
administered by intraperitoneal route once a day for two days. Test
materials were given at the time indicated after intranasal virus
exposure (1610
5 PFU). The data accompany those of Table 3 (body
weight results of treatment with mDEF208 at 10
7 PFU/mouse are not
shown). Thus, the initial number of mice per group for each figure
corresponds to the total number per group in the table.
doi:10.1371/journal.pone.0026330.g003
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production of therapeutic levels of IFN within 6 h [15]. Secondly,
in situ produced IFN must overcome a high level of IFN system
down regulation caused by the established vaccinia infection [12].
It has been demonstrated by other investigators that both
mDEF201 and DEF201 are effective as a treatment only when
given within 1–2 days after virus exposure [16,17,18,19]. How
well Ad-vectored IFN protects infected animals will depend upon
each virus’ virulence including the number and expression of
different IFN system antagonists. However, the treatment efficacy
of DEF201 in these unrelated viruses indicates real potential as a
broad spectrum antiviral, and the extrapolation of these treatment
windows into the clinical scenario may be significant.
In these studies antiviral activity depended on the amount of
mDEF201 administered, which was the case in other published
studies with unrelated viruses [16,17,18,19]. The production of a
steady-state level of interferon may bypass the need for bolus
dosing associated with traditional interferon treatment, and thus
reduce toxic side effects. Nevertheless, safety of DEF201 is a
consideration for eventual human use, and safety and toxicology
studies are ongoing. It will need to be determined how long the
IFN-induced antiviral state persists and its effects on treated
individuals.
This is the first study demonstrating that surviving mice treated
with mDEF201 are protected against re-infection with the same
virus. This is not surprising, as mDEF201 treatment did not
completely prevent vaccinia virus production in the lungs and
snouts of the animals (Figures 2A and 2F), thus driving an acquired
immune response. The veracity of that immune response in
mDEF201 treated animals most likely was weaker than it would be
in more severely infected mice, based upon weight comparisons to
surviving placebos (Figure 1B).
Assuming an adequate safety profile, one can envision the use of
DEF201 as a means of quickly providing significant protection
to first responders and medical chain personnel confronted with
a deliberate release of variola or monkeypox virus into the
environment. Even if infected, DEF201 treated individuals could
still acquire an immunity to the virus, as demonstrated by the
present studies, thus rendering them ‘vaccinated’ against future
exposure. The intranasal method of delivery of DEF201 facilitates
rapid prophylaxis in people entering a suspected poxvirus
environment. Moreover, DEF201 has the potential to treat a
large number of unrelated viruses simultaneously, for which there
are no current treatments.
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